Multiple sclerosis (MS) drugs Ocrevus and Gilenya have been linked to melanoma, with Gilenya linked to squamous cell carcinoma and basal cell carcinoma, also. These new drug safety findings come from an analysis of skin cancer cases reported to the FDA Adverse Event Reporting System (FAERS) for patients receiving certain multiple sclerosis (MS) … [Read more...]
Ocrevus PML Case Report: Patient Used Ocrevus, Only, Without Prior Tysabri or Gilenya Use
The primary source for this Ocrevus PML case report is a JAMA Neurology Brief Report item dated March 16, 2021, “Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy”. From the Abstract for that medical journal article we take this excerpt: Conclusions and … [Read more...]
Ocrevus Patient Gets Progressive Multifocal Leukoencephalopathy (PML)
A May 24, 2017 Reuters news report, “Deadly brain infection in German MS patient prompts Roche investigation”, brings some unwanted attention to a potential drug safety issue for Ocrevus (ocrelizumab injection) which may negatively affect this projected sales success. From this recent Reuters article: A person in Germany treated with Roche Holding … [Read more...]